Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Bookmark and Share
Published: 8 Jun 2021
Views: 992
Rating:
Save
Dr Joshua Sabari and Dr Anna Minchom

Dr Joshua Sabari (NYU Langone Health, New York City, USA) and Dr Anna Minchom (The Royal Marsden Hospital, London, UK) discuss the efficacy of amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFRm NSCLC and potential biomarkers for response.

Initially, Dr Minchom explains the drugs for EGFR mutant targeted pathways. They then, discuss the efficacy of amivantamab in combination with lazertinib in the context of a wider discussion of what it means for the management of patients with Exon 20 insertions.

In the end, they talk about other key developments in the treatment of patients with EGFRm NSCL and discuss the future of targeted therapy for this type of lung cancer.

This programme has been supported by an unrestricted educational grant from Janssen.